Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.

Author: BotesMariette, BurnsideRobert, ClumeckNathan, CooperDavid A, DejesusEdwin, HeeraJayvant, IvePrudence, LazzarinAdriano, MukwayaGeoffrey, SaagMichael, WalmsleySharon, van Der RystElna

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Maraviroc maintained similar long-term antiviral efficacy to efavirenz over 5 years in treatment-naive patients with CCR5-tropic HIV-1. Maraviroc was generally well tolerated with no unexpected safety findings or evidence of long-term safety concerns.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Maraviroc, a chemokine co-receptor type 5 (CCR5) antagonist, has demonstrated comparable efficacy and safety to efavirenz, each in combination with zidovudine/lamivudine, over 96 weeks in the Maraviroc vs. Efavirenz Regimens as Initial Therapy (MERIT) study. Here we report 5-year findings...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940293/

データ提供：米国国立医学図書館（NLM）

Maraviroc: A Long-Term Solution in the Desert of HIV Treatment

HIV infection is like a relentless desert storm, constantly attacking the immune system. This research evaluates the long-term efficacy and safety of maraviroc, a CCR5 antagonist, compared to efavirenz, a standard HIV treatment, in treatment-naive patients with CCR5-tropic HIV-1. It's like comparing two different approaches to navigating a challenging desert, seeking the most effective and safe path.

A Long and Winding Road: A Journey of Discovery

The study, like a long desert expedition, meticulously analyzes the effectiveness of maraviroc over a five-year period. It's like navigating a complex desert landscape, seeking the right path to a sustainable solution. The researchers found that maraviroc maintained similar long-term antiviral efficacy to efavirenz, demonstrating its potential as a valuable treatment option for HIV patients.

A New Oasis of Hope: Toward a Brighter Future

The study's findings offer hope for a brighter future for HIV patients. It's like finding a hidden oasis in the desert, providing a long-term solution for managing this challenging condition. Maraviroc's long-term efficacy and safety profile suggest a potential for improving HIV treatment outcomes and enhancing the quality of life for patients.

Dr. Camel's Conclusion

This research is like a desert oasis, offering hope and a promising new solution for HIV treatment. It's a testament to the ongoing advancements in HIV research and underscores the importance of developing long-term therapies for this challenging condition.

Date :
  1. Date Completed 2015-02-20
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24983542

DOI: Digital Object Identifier

PMC3940293

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.